ZBIO - Zenas Biopharma Inc Company Buyout Price

Zenas Biopharma Inc (ZBIO) develops immune drugs, relying on external contractors to conduct all testing and manufacture products. The business possesses high macro-resilience, as the lengthy research cycle makes it independent of market cyclicality. The current enterprise value is 1620.95. The price action below highlights significant risks associated with the outcome of Obexelimab trials and a high cash burn rate.

For a comparative asset analysis, investors utilize Enterprise Value as an objective price for a full business buyout. This metric sums market capitalization and debt, subtracting cash and cash equivalents. For Zenas Biopharma Inc (ZBIO), this calculation is critical, as the lack of revenue prior to FDA approval makes the company dependent on its existing cash reserves. By analyzing the history of enterprise value metrics on GURU.Markets, one can assess the risk of overpaying for the potential of the antibodies.